Early versus delayed autologous stem cell transplant in patients receiving novel therapies for multiple myeloma

• DOI: 10.3109/10428194.2012.751528
• Publication Date: 2012-11-29T17:03:32Z
• Authors: Neil C. Dunavin; Lai Wei; Patrick Elder; Gary S. Phillips; Don M. Benson; Craig C. Hofmeister; Sam Penza; Carli Greenfield; Karen S. Rose; Gisele Rieser; Lisa Merritt; Jill Ketcham; Nyla Heerema; John C. Byrd; Steven M. Devine; Yvonne A. Efebera
• Keywords: Autologous stem-cell transplantation

Autologous stem cell transplant (ASCT) is an effective treatment for multiple myeloma (MM). However, the timing of ASCT in era novel agents (lenalidomide, thalidomide, bortezomib) unknown. We retrospectively reviewed outcome patients with MM who received agent-based induction and first within 12 months diagnosis (early ASCT, n = 102) or at a later date (late 65). Median time to was 7.9 vs. 17.7 early late ASCT. The 3- 5-year overall survival (OS) from 90 63% 82 respectively (p 0.45). Forty-one 36 groups have relapsed progressed, median relapse 28 23 0.055). On multivariable analysis, factors predictive increased risk progression were International Scoring System (ISS) stage III 0.007), less than very good partial response (< VGPR) post-ASCT < 0.001). A factor worst OS being on hemodialysis 0.037). No superiority one agent seen. In summary, viable option receiving targeted therapies.